Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 14/20 | 0.51 |
| ▸ | CCR9 | P51686 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4711667 | 0.92 | KDM4E (0.41) | CCR2TNIKBRD4MCHR1MAPT | |
| SCHEMBL4716301 | 0.89 | MAPT (0.44) | CCR2TNIKBRD4MAPT | |
| SCHEMBL5119050 | 0.83 | CCR2 (0.62) | CCR2CCR9GPR35MAPT | |
| SCHEMBL4715116 | 0.82 | CCR2 (0.55) | CCR2CCR9GPR35BRD4MAPT | |
| SCHEMBL4715213 | 0.76 | CCR2 (0.51) | CCR2BRD4MAPT | |
| SCHEMBL4711188 | 0.74 | BRD4 (0.53) | CCR2BRD4MAPT | |
| SCHEMBL4717022 | 0.74 | CCR2 (0.49) | CCR2BRD4MAPT | |
| SCHEMBL4712174 | 0.74 | MAPT (0.51) | CCR2BRD4MAPT | |
| SCHEMBL4715522 | 0.73 | RGS4 (0.48) | CCR2BRD4MAPT | |
| SCHEMBL4715185 | 0.73 | BRD4 (0.48) | CCR2BRD4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456286-B2 | Bicyclic heteroaromatic compounds as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2008-11-25 | — | — | US | disclosed |
| EP-1549648-B1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2008-11-12 | — | — | EP | disclosed |
| US-20060122212-A1 | Bicyclic heteroaromatic compounds as kinase inhibitors | CELLTECH R&D LIMITED (GB) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122212-A1 | Bicyclic heteroaromatic compounds as kinase inhibitors | MAP2K2, MAP2K7, MAP2K3 | CCR2 333/4885CCR9 901/4885GPR35 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.